UK Study Shows Rifaximin-a Significantly Reduces Hospital Resource use for Patients With Hepatic Encephalopathy

LONDON, April 14, 2016 /PRNewswire/ --

Norgine B.V. today presented new positive UK real world practice data from the IMPRESS retrospective observational study for rifaximin-alpha at the International Liver Congress 2016, 13-16 April in Barcelona, Spain. These data showed that in UK clinical practice, treatment with rifaximin-alpha for hepatic encephalopathy:

- is well tolerated
- is associated with reductions in hospitalisation frequency, bed occupancy (including
critical care) and emergency room visits - within six months of treatment initiation
and sustained at 12 months.

(Logo: )

The IMPRESS retrospective observational study included 11 specialist National Health Service (NHS) centres and 145 patients prescribed rifaximin-alpha for hepatic encephalopathy between July 2008 and May 2014.

Peter Martin, COO at Norgine said; "These positive real life use results for rifaximin-alpha prove that this treatment is not only well tolerated but also reduces hospital resource. By using rifaximin-alpha healthcare systems can make substantial savings as it reduces hospitalisations and bed occupancy within six months of treatment. Hepatic encephalopathy has a huge impact on the lives of patients - as often they are not able to care for themselves, their families, careers and health systems overall and rifaximin-alpha can help reduce this burden."

Norgine currently holds marketing rights for XIFAXAN(R) 550mg (known as TARGAXAN(R) Black Triangle Drug 550 in the UK and some other markets) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland. Norgine and Alfa Wassermann co-promote the product under the TIXTAR(R) brand name in France.

The product is reimbursed in Australia, England, Germany, Ireland, Luxembourg, New Zealand, Norway, Scotland, Sweden, Switzerland and Wales.

To view the full press release go to

Media Contacts: 
Isabelle Jouin, T: +44-(0)1895-453643 
Charlotte Andrews, T: +44-(0)1895-453607 
Follow us @norgine 



Norgine B.V.

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234